Alexendar Henry Zisson

Partner at Thomas, McNerney & Partners LLC

Alexendar Henry Zisson

Alexendar Henry Zisson

Partner at Thomas, McNerney & Partners LLC

Overview
RelSci Relationships

631

Number of Boards

9

Birthday

1970

Age

48

Relationships
RelSci Relationships are individuals Alexendar Henry Zisson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Financial Officer & Senior Vice President-Corporate Development at Profound Medical Corp.

Relationship likelihood: Strong

Co-Founder at Altair Therapeutics, Inc.

Relationship likelihood: Strong

Founder at InnoPharma, Inc.

Relationship likelihood: Strong

Chief Operating Officer & Executive Director at InnoPharma, Inc.

Relationship likelihood: Strong

Founder, Chairman, Chief Executive Officer & President at Clarus Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder & Partner at Thomas, McNerney & Partners LLC

Relationship likelihood: Strong

President & Chief Executive Officer at Tekla Capital Management LLC

Relationship likelihood: Strong

Managing Director at H.I.G. BioHealth Partners LLC

Relationship likelihood: Strong

Director at Ocera Therapeutics, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer at ImClone LLC

Relationship likelihood: Strong

Paths to Alexendar Henry Zisson
Potential Connections via
Relationship Science
You
Alexendar Henry Zisson
Partner at Thomas, McNerney & Partners LLC
Education
MS

Brown University is located in historic Providence, Rhode Island and was founded in 1764. It is the seventh-oldest college in the United States. Brown is an independent, coeducational Ivy League institution comprising undergraduate and graduate programs, plus the Alpert Medical School, School of Public Health, School of Engineering, and the School of Professional Studies.

Career History
Managing Director
2016 - Current

H.I.G. BioHealth Partners LLC invests in a broad range of life science opportunities across sectors and stages. The firm has extensive and diverse experience in big pharm, small biotech, medical devices, diagnostics, basic science, clinical research and technology transfer. They invest in companies developing novel products for significant unmet medical needs, primarily in the following sectors: (1) therapeutics including small molecules, protein therapeutics, antibodies, etc. (2) medical devices and (3) diagnostics. Investments typically range from $3 million to $40 million.

Partner
2002 - Current

Thomas, McNerney & Partners (TMP) invests in life science and medical technology companies at all stages of development. The firm targets investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. They are particularly interested in companies that are developing therapeutic products for life threatening or costly, chronic health conditions.TMP may invest in start-up companies, provide growth capital to emerging companies and participate in restructuring transactions including spin-outs, roll-ups and recapitalizations.TMP typically invests $5 million to $40 million in one or more rounds of financing, with an average investment of more than $15 million over the life of an investment. Initial investments may be as small as $100,000. The firm prefers to lead the financing round in which they first participate.TMP looks for companies with a focus on large, rapidly growing and underserved market segments that are ready to undergo change. Companies should be able to achieve a leadership position or have already established one in targeted market segments. They should have a convincing business model with the potential to achieve significant, sustainable value with reasonable risk. TMP also seeks companies with strong leadership, reasonable regulatory timelines with well-defined endpoints, technology development that integrates existing technologies in new ways, a case for acceptable product reimbursement and a solid intellectual property position.

Professional
Current
Boards & Committees
Board Member
Current

InnoPharma, Inc. provides pharma drugs. The firm is a developer of sterile generic and specialty pharmaceutical products. It works with manufacturing and clinical research organizations worldwide for commercialization of its developed products. The company was founded by Navneet Puri and Sriram J. Ramanathan in 2005 and is headquartered in Piscataway, NJ.

Director
Current

Clarus Therapeutics, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company was founded by Robert E. Dudley in February 2004 and is headquartered in Northbrook, IL.

Director
Prior

Health Sciences North Research Institute operates as a non profit organization that focuses on contributing to solutions for health challenges faced by Ontario's Northern and Indigenous communities. The company was founded on June 16, 2011 and is headquartered in Sudbury, Canada.

Transactions
Details Hidden

Auspex Pharmaceuticals, Inc. issued Common Stock